Hemostemix Inc. (CVE:HEM – Get Free Report) was up 15.4% during trading on Wednesday . The company traded as high as C$0.24 and last traded at C$0.23. Approximately 382,000 shares traded hands during mid-day trading, a decline of 37% from the average daily volume of 601,939 shares. The stock had previously closed at C$0.20.
Hemostemix Stock Performance
The firm has a market capitalization of C$19.60 million, a P/E ratio of -11.25 and a beta of 0.20. The firm has a 50 day simple moving average of C$0.10 and a two-hundred day simple moving average of C$0.08.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- How to Calculate Retirement Income: MarketBeat’s Calculator
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
- The 3 Best Retail Stocks to Shop for in August
- What Goldman Sachs’ Quarterly Results Reveal About the Economy
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- 3 Dividend Stocks at Bargain Levels to Defend Your Portfolio
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
